# JC06 Rec'd PCT/PTO 12 MAY 2005

#### **PATENT**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	: Jorge Setoain Quinquer, et al.	
For:	: COMPOUNDS WHICH CAN BE USE	ΞD
	: TO DIAGNOSE AND MONITOR	
	: DISEASES ASSOCIATED WITH TH	E
	: FORMATION OF AMYLOID PROTE	I
	: FIBRILS	
	:	
Serial No.	: New	
	:	
Filed	: May 12, 2005	
	:	
Art Unit	: Unassigned	
	:	
Examiner	: Unassigned	
Attorney Docket No.	: ABG 3002	
	:	
Confirmation No.	: Unassigned	

#### INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted:

<u>X</u>	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
	under 37 CFR 1.97(c) together with either a:  Certification under 37 CFR 1.97(e), or  a \$180.00 fee under 37 CFR 1.17(p), or  (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

10/534749

JC06 Rec'd PCT/PTO 12 MAY 2005 Attorney Docket No.: ABG 3002

 under 37 CFR 1.97(d) together with a:
Certification under 37 CFR 1.97(e), and
a petition under 37 CFR 1.97(d)(2)(ii), and
a \$180.00 petition fee set forth in 37 CFR 1.17(i)(1).
(Filed after final action or notice of allowance, whichever occurs first, but
before payment of the issue fee)

Applicants submit herewith Form PTO/SB/08A Information Disclosure Statement by Applicant together with copies, of patents, publications or other information of which applicants are aware, which applicants believe may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicants are aware.

Applicants submit that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

In the event that the fees submitted prove to be insufficient in connection with the filing of this paper, please charge our deposit account number 50-0578 and please credit any excess fees to such Deposit Account.

> Respectfully submitted, KRAMER & AMADO, P.C.

Reg. No. 51,399

KRAMER & AMADO, P.C.

Crystal Plaza One

2001 Jefferson Davis Highway

Suite 1101

Arlington, Virginia 22202

Telephone No.: (703) 413-5000 Facsimile No: (703) 413-5048

## JC06 Rec'd PCT/PTO 12 MAY 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to re-

Substitute for form 1449/PTO

Sheet 1

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	New 0 / 2 2 4 / 4 9			
Filing Date	May 12, 2005			
First Named Inventor	Jorge Setoain Quinquer			
Art Unit	Unassigned			
Examiner Name	Unassigned			
Attorney Docket Number	ARG 3002			

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	1	US- 4,360,509	11/23/1982	Goedemans	
	2	<sup>US-</sup> 2002/0025944	02/28/2002	Bush, et al.	•
		US-			
		U\$-			
		US-			

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	WW-DD-AAAA	, , , , , , , , , , , , , , , , , , , ,	Or Relevant Figures Appear	T°
	3	WO 98/06403	02/19/1998	GEROLYMATOS, S.A.		
	• 4	WO 02/24652	03/28/2002	PHARM. & UPJOHN		
_						_
						<u>L</u>
	1				ĺ	L

Examiner		Date	
Signature	•	Considered	
C.g. attaco			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.